Search Results for "ciprofloxacin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for ciprofloxacin. Results 11 to 20 of 92 total matches.
Rifaximin (Xifaxan) for Travelers' Diarrhea
The Medical Letter on Drugs and Therapeutics • Sep 13, 2004 (Issue 1191)
, self-treatment with a 3-day course of
ciprofloxacin, levofloxacin, norfloxacin, or ofloxacin ...
Rifaximin (Xifaxan - Salix), a non-absorbed oral antibiotic derived from rifampin (Rifadin, and others), has been approved by the FDA for treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli in patients 12 years of age or older. It has been available in Europe since 1987.
Addendum: Cost of Drugs for Acute Cystitis
The Medical Letter on Drugs and Therapeutics • Aug 20, 2012 (Issue 1397)
at all.
Not recommended: Ciprofloxacin – Fluoroquinolones
should not be used empirically to treat acute uncomplicated ...
A reader suggested that our July 23 article on Drugs for Urinary Tract Infection (Med Lett Drugs Ther 2012; 54:57)1 should have included information on the cost of the drugs we recommended for treatment of acute uncomplicated cystitis.Trimethoprim/sulfamethoxazole DS — Generic formulations are available at large discount pharmacies for $4 for 20 tablets. Trimethoprim/sulfamethoxazole DS is generally found on tier 1 (lowest co-pay) of insurance company formularies.Nitrofurantoin monohydrate/macrocrystals — The wholesale acquisition cost of the generic formulation is about $2.50 per tablet...
Enoxacin - A New Fluoroquinolone
The Medical Letter on Drugs and Therapeutics • Nov 13, 1992 (Issue 883)
of reports of a high incidence of hemolysis and renal dysfunction. Ciprofloxacin (Cipro) and ofloxacin ...
Enoxacin (en ox' a sin; Penetrex - Rh ne-Poulenc Rorer), a fluoroquinolone antimicrobial for oral use, has now been marketed in the USA for treatment of urinary tract infections and uncomplicated urethral or cervical gonorrhea.
Anthrax Vaccine
The Medical Letter on Drugs and Therapeutics • May 08, 1998 (Issue 1026)
, doxycycline, erythromycin, streptomycin and ciprofloxacin, among others, but
resistant to third-generation ...
Now that US Secretary of Defense has decided to vaccinate more than 2 million memebers of the US armed forces against anthrax, US physicians may be asked to answer some questions about the vaccine and the disease.
Grepafloxacin--A New Fluoroquinolone
The Medical Letter on Drugs and Therapeutics • Jan 30, 1998 (Issue 1019)
axetil − Ceftin (Glaxo Wellcome) 250-500 mg bid 72.91-138.31
Ciprofloxacin − Cipro (Bayer) 500-750 mg ...
Grepafloxacin (Raxar - Glaxo Wellcome), a once-daily oral fluoroquinolone, is now being marketed for treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, uncomplicated gonorrhea, and nongonococcal urethritis and cervicitis.
Sparfloxacin and Levofloxacin
The Medical Letter on Drugs and Therapeutics • Apr 25, 1997 (Issue 999)
aureus. However,
methicillin-resistant staphylococci that are resistant to ciprofloxacin, now a high ...
Sparfloxacin (Zagam - Rh ne-Poulenc Rorer) and levofloxacin (Levaquin - Ortho-McNeil) are the newest fluoroquinolone antimicrobials to be approved by the US Food and Drug Administration. Sparfloxacin in a once-daily oral preparation is being marketed for treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis. Levofloxacin, which is the active stereoisomer of ofloxacin (Floxin), is available for either oral or parenteral use; it is approved for oncedaily treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis,...
Raxibacumab for Anthrax
The Medical Letter on Drugs and Therapeutics • Apr 01, 2013 (Issue 1413)
, such as ciprofloxacin or doxycycline,
for 60 days.1 In rhesus monkey studies, vaccination
at 0 and either 2 or 4 weeks ...
The FDA has approved raxibacumab (rax” ee bak’ ue
mab; GSK), a fully human monoclonal antibody given by
intravenous infusion, for treatment of inhalational anthrax
in combination with appropriate antibacterial drugs, and
for prophylaxis of inhalational anthrax when alternative
therapies are not available or are not appropriate. It was
approved under the Animal Efficacy Rule, which allows
the FDA to approve drugs that demonstrate efficacy in
animals, providing that they would have a reasonable
human health benefit and are safe for human use.
Raxibacumab is only available from the...
Drugs and Vaccines Against Biological Weapons
The Medical Letter on Drugs and Therapeutics • Oct 15, 2001 (Issue 1115)
, amoxicillin, chloramphenicol, tetracyclines, ciprofloxacin and other fluoroquinolones, among others ...
Concerns have arisen anew about possible use of biological weapons. The pathogens considered most likely to be used for this purpose are discussed in this article. A good source for additional information is www.usamriid.army.mil/education/bluebook.html.
In Brief: Fluoroquinolones and Peripheral Neuropathy
The Medical Letter on Drugs and Therapeutics • Nov 11, 2013 (Issue 1429)
Adverse Event Reporting
System (AERS) database.1
Ciprofloxacin (Cipro)
Gemifloxacin (Factive ...
The FDA is requiring new warnings about peripheral neuropathy in the labeling of all oral and injectable fluoroquinolones. The potential for this class of antibiotics to cause peripheral neuropathy was first identified more than 10 years ago and a warning was added to their labels in 2004. The new warnings are based on a recent review of the FDA’s Adverse Event Reporting System (AERS) database.1The onset of peripheral neuropathy can occur rapidly, often within a few days of starting a fluoroquinolone, and in some patients the disorder may be permanent. Symptoms include pain, tingling,...
Trovafloxacin
The Medical Letter on Drugs and Therapeutics • Mar 13, 1998 (Issue 1022)
USED FLUOROQUINOLONES
Drug Daily dosage* Cost*
Oral
Ciprofloxacin − Cipro (Bayer) 500 to 750 mg bid ...
Trovafloxacin (Trovan - Pfizer) and its prodrug alatrofoxacin (Trovan IV) are new fluroroquinolones marketed for an unusually wide variety of infections, including oral and intravenous treatment of nosocomial and community-acquired pneumonia, acute ecerbations of chronic bronchitis, acute sinusitis, complicate intra-abdominal and pelvic infections, diabetic foot infection, uncomplicated urinary tract infection, prostatitis, cervicitis and uncomplicated gonorrhea.